The DayOne Digital Health Accelerator Program
DayOne focus on healthcare innovation driven by digital health solutions. Together with … Continue reading “The DayOne Digital Health Accelerator Program”
DayOne focus on healthcare innovation driven by digital health solutions. Together with … Continue reading “The DayOne Digital Health Accelerator Program”
London, UK – 21 October 2021 – Leucid Bio (“Leucid” or the “Company”), … Continue reading “Leucid Bio Raises £11.5M in Series A Financing to Develop Next Generation of Innovative Chimeric Antigen Receptor T cell (CAR-T) Therapies”
Industry veteran in oncology antibody discovery & development Dr Haijun Sun appointed … Continue reading “ONA Therapeutics Strengthens Scientific Leadership Team”
Funds will be used to support the development of pioneering mammary biotechnology … Continue reading “Novo Holdings Leads US$21M Series A Financing in BI-OMILQ”
October 18, 2021 Early data from Phase 1/2 clinical trial in pediatric … Continue reading “LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children”
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology … Continue reading “Pyxis Announces Pricing of Upsized Initial Public Offering”
LONDON, 18 October 2021: Arix Bioscience plc (“Arix” or the “Company”) (LSE: … Continue reading “Arix Bioscience plc Business Update and Cancellation of Share Buyback”
Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce … Continue reading “Destiny Pharma: Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus”
ALAMEDA, Calif. & CAMBRIDGE, UK – October 14, 2021 – Exelixis, Inc. (Nasdaq: … Continue reading “Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes”
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative … Continue reading “Futura Medical plc Board Appointment”
– Completed enrolment of 150 pregnant women in a Phase 2 study … Continue reading “MinervaX provides clinical and leadership update”
Mårten Steen Promoted to Co-Managing Partner Expanded team with the appointment of … Continue reading “HEALTHCAP STRENGTHENS SENIOR TEAM”
LONDON, 6 October 2021: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), … Continue reading “Arix today announces the following updates to its Board and Executive team”
Industry veteran with decades of experience in company formation, scientific research, and … Continue reading “Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer”
The Hague, Netherlands, 5 October 2021: Amber Implants, an innovative medical technology company … Continue reading “Amber Implants VCFix® spinal system receives US FDA Breakthrough Designation”
DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric Healthcare For development of … Continue reading “DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric Healthcare”
Torsten Mummenbrauer, Chief Executive Officer of ExeVir will be speaking on a … Continue reading “ExeVir Bio BV announces its participation in the 8th Annual Healthtech Investment Forum organized by SACHS Associates taking place virtually 5th-6th October 2021.”
Isabel Ferreira speaking on the “Platform Technologies and Novel Therapeutics” Panel Versameb … Continue reading “Versameb at Sachs 21st Annual Biotech in Europe Forum”
– World Class Speakers from Biotech & Healthcare Industry and Investment Community – … Continue reading “Optimum Strategic Communications Hosts 13th Annual Healthcare Investor Conference”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
